What a U.S. Study Found About the Shingles Vaccine and Dementia
MedPage Today • • health
Key Points:
- Analysis of 1.5 million Medicare beneficiaries found that older adults receiving the two-dose recombinant zoster (shingles) vaccine (Shingrix) had a 33% lower risk of developing any dementia within 3 years compared to unvaccinated peers.
- The study reported a 28% reduced risk of Alzheimer's disease and a 33% reduced risk of vascular dementia among vaccinated individuals during the same follow-up period.
- Over longer follow-up of more than 3 years, the vaccine continued to show protective associations, though with slightly reduced effect sizes for Alzheimer's disease and any dementia.
- This large, contemporary Medicare cohort study supports growing real-world evidence linking shingles vaccination to lower dementia risk, but researchers emphasize the need for clinical trials and mechanistic studies to confirm causality.
- Limitations include potential misclassification of dementia diagnoses and unmeasured confounding factors such as education and lifestyle; further research is necessary to clarify the vaccine’s protective role against dementia.
